Stock HRTX HERON THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Heron Therapeutics, Inc.

Equities

HRTX

US4277461020

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.45 USD -3.92% Intraday chart for Heron Therapeutics, Inc. -7.20% +44.12%
Apr. 23 Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target MT
Mar. 21 Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024 CI

Business Summary

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

Number of employees: 126

Sales per Business

USD in Million2022Weight2023Weight Delta
Therapeutic Innovations
100.0 %
108 100.0 % 127 100.0 % +17.99%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
108 100.0 % 127 100.0 % +17.99%

Managers

Managers TitleAgeSince
Craig Collard CEO
 Chief Executive Officer 58 23-02-20
Ira Duarte DFI
 Director of Finance/CFO 55 23-06-15
Chris Storgard CTO
 Chief Tech/Sci/R&D Officer 58 18-10-31
Thomas B. Ottoboni CTO
 Chief Tech/Sci/R&D Officer 65 12-03-29
John C. Arthur PRN
 Corporate Officer/Principal 58 16-12-31
Sean T. Ristine HRO
 Human Resources Officer 54 14-07-31
William Forbes PRN
 Corporate Officer/Principal 62 23-06-05

Members of the board

Members of the board TitleAgeSince
Craig Collard CEO
 Chief Executive Officer 58 23-02-20
Susan Rodriguez BRD
 Director/Board Member 60 21-09-19
Craig Johnson BRD
 Director/Board Member 62 14-01-12
Christian Waage BRD
 Director/Board Member 57 16-06-21
Adam Morgan CHM
 Chairman 45 23-02-20
Sharmila Dissanaike BRD
 Director/Board Member 49 21-09-19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 150,328,585 148,907,948 ( 99.05 %) 0 99.05 %

Shareholders

NameEquities%Valuation
Rubric Capital Management LP
17.77 %
26,713,503 17.77 % 74 M $
Vanguard Fiduciary Trust Co.
5.547 %
8,338,912 5.547 % 23 M $
Velan Capital Investment Management LP
4.648 %
6,986,744 4.648 % 19 M $
Velan Capital Investment Management LP
4.648 %
6,986,744 4.648 % 19 M $
BlackRock Advisors LLC
4.558 %
6,851,843 4.558 % 19 M $
Fiduciary Trust Company International
4.261 %
6,404,795 4.261 % 18 M $
Clearline Capital LP
4.037 %
6,068,554 4.037 % 17 M $
OrbiMed Advisors Private Equity
3.944 %
5,928,591 3.944 % 16 M $
Tejara Capital Ltd.
3.509 %
5,275,236 3.509 % 15 M $
Palisade Capital Management LP
2.425 %
3,646,103 2.425 % 10 M $

Company contact information

Heron Therapeutics, Inc.

4242 Campus Point Court Suite 200

92121, San Diego

+858 251 4400

http://www.herontx.com
address Heron Therapeutics, Inc.(HRTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Heron Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.45 USD
Average target price
6.75 USD
Spread / Average Target
+175.51%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
HERON THERAPEUTICS, INC. Stock Heron Therapeutics, Inc.
+44.12% 368M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+48.43% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. HRTX Stock
  4. Company Heron Therapeutics, Inc.